Filtrer vos résultats
- 2
- 1
- 1
- 2
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective studyJournal of Crohn's and Colitis, 2020, 14 (1), pp.S547. ⟨10.1093/ecco-jcc/jjz203.793⟩
Article dans une revue
hal-03551537v1
|
||
|
Efficacy of ustekinumab in perianal Crohn's disease: the BioLAP multi-centre observational study14. Congress of ECCO, European Crohn’s and Colitis Organisation, Mar 2019, Copenhague, Denmark. ⟨10.1093/ecco-jcc/jjy222.108⟩
Communication dans un congrès
hal-03552295v1
|